Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
152
resultados
Última actualización
13/09/2026 [07:28:00]
Resultados 100 a 125 de 152
Resumen de: WO2026158331A1
Provided are a traditional Chinese medicine for preventing and/or treating Parkinson's disease and a method for preparing same. The traditional Chinese medicine comprises the following raw materials in parts by weight: 10-15 parts of Gastrodiae Rhizoma, 5-10 parts of Juglandis Semen, 30-40 parts of honey, 30 parts of Rosa roxburghii, and 5-8 parts of lemon. The traditional Chinese medicine has significant effects on the prevention and/or treatment of Parkinson's disease, and features simple composition, mild adverse effects, and good drug stability.
Resumen de: US20260217678A1
Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease. Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds of formula (I) are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease.
Resumen de: WO2026158687A1
The present invention relates to the technical field of antibody drugs, and in particular, to an anti-N3pE amyloid-β antibody and the use thereof, and a pharmaceutical composition containing the anti-N3pE amyloid-β antibody. The anti-N3pE amyloid-β antibody exhibits a significantly excellent affinity, stability and specificity. In addition, further provided is the use of the anti-N3pE amyloid-β antibody for treating diseases caused by amyloid-β (e.g., Alzheimer's disease, Down syndrome, cerebral amyloid angiopathy, etc.).
Resumen de: WO2026158729A2
Provided in the present application are a pathogenic factor of neurodegenerative diseases and the use thereof. The pathogenic factor of neurodegenerative diseases is a PSAP-GPR37-IL-6 signaling axis. The present application specifies for the first time the action mechanism of the PSAP-GPR37-IL-6 signaling axis as a pathogenic factor of neurodegenerative diseases (especially Parkinson's disease), and reveals that oligodendrocytes regulate the molecular pathway of neuroinflammation and neurodegenerative changes via the signaling axis, thus filling the research gap in the prior art regarding the participation of oligodendrocytes in the pathogenesis of PD.
Resumen de: TW202530251A
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
Resumen de: EP4782449A1
0001 The present invention provides a use of an SARM1 enzyme activity inhibitor in treating neurodegenerative diseases or neurological diseases or conditions, and specifically provides a compound of formula (I) acting as an SARM1 enzyme activity inhibitor, and a pharmaceutical composition thereof.
Resumen de: EP4782003A1
The present application relates to a novel therapeutic agent for treating Parkinson's disease and a method for treating Parkinson's disease using the same.
Resumen de: WO2025061918A1
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
Resumen de: EP4782452A1
A compound represented by formula (I) and a use thereof in the preparation of a drug. The invention relates to a novel compound having an IRAK4 degradation effect, which can effectively degrade IRAK4 or otherwise inhibit IRAK4 activity. The invention has very good prospects for application in IRAK4-mediated diseases, including immune diseases, tumors, Alzheimer's disease, and fibrotic diseases, and provides a new choice for clinical screening and/or preparation of drugs related to IRAK4 activity.
Resumen de: US20260207794A1
The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates (such as Parkinson's disease or such as multiple system atrophy (MSA)) determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.
Resumen de: WO2026152919A1
The present invention relates to the field of biopharmaceutical technology, and in particular, to a dual-drug nanoparticle for treating Alzheimer's disease, a method for preparing same, and use thereof. An Aβ inhibitor is connected to an amphiphilic polymer via a chemical bond. The amphiphilic polymer connected with the Aβ inhibitor is mixed with a STING inhibitor, and the mixture is slowly added dropwise into water under ultrasonication. After ultrasonication and filtration, the supernatant is taken to obtain the dual-drug nanoparticle. The dual-drug nanoparticle prepared by the present invention has good biocompatibility and stability, and can cross the blood-brain barrier and act on both the Aβ and microglial STING pathways, so as to depolymerize Aβ and promote Aβ clearance, inhibit the activation of the microglial STING pathway, and reduce the release of inflammatory factors that damage neurons. The dual-drug nanoparticle can significantly reduce Aβ deposition in the brain and significantly inhibit the activation of the microglial STING pathway in the brain, such that the memory ability and spatial recognition ability of mice are remarkably improved, and the inflammatory microenvironment in the brain is ameliorated.
Resumen de: US20260209350A1
0000 The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
Resumen de: AU2025231111A1
Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: WO2026156335A1
Small molecule mimetics of Carboxypeptidase E (CPE) and related compositions, methods, and systems for providing cytoprotection. Compounds of Formula I, which encompasses specific sub-sets including hydrazone-based (Formula II, III, IV), urea-based (Formula V), and amide-based (Formula VI) scaffolds are configured to bind selectively to the 5-Hydroxytryptamine Receptor 1E (5-HTR1E) to serve as functional mimetics of the neurotrophic protein CPE. Upon binding, the compounds trigger a specific biased signaling pathway that involves the recruitment of beta-arrestin, phosphorylation of ERK, and upregulation of the anti-apoptotic protein BCL-2. The compounds exhibit nanomolar binding affinity and significant cytoprotective activity against oxidative stress in human neurons and peripheral tissues. Also methods for identifying such mimetics using a hybrid virtual screening protocol, synthetic methods comprising a Betti reaction sequence, and therapeutic methods for treating conditions associated with oxidative stress, such as neurodegenerative disorders (e.g., Alzheimer's Disease) and peripheral organ injury, via intranasal or systemic administration.
Resumen de: AU2026205314A1
Abstract Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided. These dosage regimens find use in the treatment of subjects having or at risk of developing amyotrophic lateral sclerosis. Abstract ul b s t r a c t u l
Resumen de: WO2026155574A1
The present invention relates to a papillomavirus virus-like particle-based anti-amyloid beta Alzheimer's disease vaccine and to a vaccine for the purpose of preventing and treating amyloid beta-associated diseases in animals. Specifically, the present invention relates to an Alzheimer's disease vaccine in which an amyloid beta antigenic group is loaded onto virus-like particles of human papillomavirus (HPV). According to the present invention, an amyloid beta peptide fragment is linked to HPV VLPs having excellent structural and immunological properties, thereby greatly enhancing the effect of inducing antibodies against amyloid beta. In addition, it was confirmed that the vaccine prepared according to the present invention exhibits superior immunogenicity and seroconversion rate compared to conventional VLP-based Alzheimer's disease vaccines.
Resumen de: WO2026154410A1
Described herein are novel compounds capable of binding to the protein synapsin III and reducing the fibrillar aggregates of said protein with alpha-synuclein. The novel compounds of the invention are therefore suitable for use in the therapeutic treatment of neurodegenerative diseases such as, in particular, Parkinson's disease, Lewy body dementia, multiple system atrophy, and the Lewy body variant of Alzheimer's disease. A pharmaceutical composition comprising the compounds according to the invention in a pharmaceutically acceptable carrier, as well as in combination with optional adjuvants, stabilizers and/or preservatives, is also described.
Resumen de: WO2026156364A1
Provided herein is the identification of target proteins for determination of clinical aspects of Alzheimer's disease in a subject. Further provided are methods for diagnosing Alzheimer's disease, determining the progression or rate of memory decline of Alzheimer's disease, and predicting amyloid-tau status, brain amyloidosis status, and plasma p-tau217 status of a subject, using predictor value comparison to thresholds. Also provided are methods of selecting a subject for inclusion in a clinical trial, methods for treating the subject in need thereof, and kits providing the same.
Resumen de: WO2026156134A1
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof T-L-B (I), useful for the modulation of TYK2 protein via degradation, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of autoimmune disorders like type 1 diabetes, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, systemic sclerosis, psoriasis, Crohn's disease, ulcerative colitis, proteasome-associated autoinflammatory syndromes (PRAAS), ISG15 deficiency, and inflammatory bowel disease; inflammatory disorders like rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, STING-associated vasculopathy with onset in infancy (SAVI). and inflammatory bowel disease; proliferative disorders like hematological cancer, polycythemia vera, myelofibrosis, essential thrombocythemia, and thrombocytosis; endocrine disorders like polycystic ovary' syndrome, Crouzon's syndrome, and type 1 diabetes; neurological disorders like Alzheimer's disease. Aicardi-Goiuteieres syndrome (AGS). Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia: and/or disorders associated
Resumen de: US20260209695A1
0000 Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other secondary Parkinsonian disorders. Disclosed are DA neuronal cells that have been modified in vitro with a genetic insertion of GDNF. The GDNF coding sequence is inserted under the transcriptional control of a promotor such that secreted proteins are made and taken up by the endogenous cells after the administered engineered cells have matured to a Neuronal Mature Cell Type to promote survival of endogenous neurons. Also disclosed are DA neuronal cells that have been modified with a genetic insertion of GBA in vitro and are hemizygous null for SNCA. The GBA coding sequence is inserted under the transcriptional control of a ubiquitous promotor and the secreted proteins are made and taken up by the graft and endogenous cells immediately upon transplantation to promote long-term graft integrity.
Resumen de: US20260207575A1
Provided herein a method of treating Juvenile Huntington disease in a subject in need thereof comprising orally administering a pharmaceutical composition comprising pridopidine and/or its analog or a pharmaceutically acceptable salt thereof.
Resumen de: US20260209725A1
0000 Compounds, compositions, uses, and methods for increasing cell viability of a dopaminergic neuron, or for preventing or treating dopaminergic neuronal death, are provided herein. In certain examples, methods for reducing symptoms and/or for preventing or treating Parkinson's disease in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a
Resumen de: WO2026152239A1
The present disclosure provides oral film compositions for transmucosal delivery of xanomeline and trospium chloride for treating schizophrenia and Alzheimer's disease. The compositions comprise xanomeline or a pharmaceutically acceptable salt thereof, trospium or a pharmaceutically acceptable salt thereof, at least one film-forming polymer, and d-alpha- tocopheryl polyethylene glycol succinate (TPGS) as a permeation enhancer, wherein the composition has a pH of from about 4.5 to about 7. The formulations address challenges including poor aqueous solubility, pH-dependent stability, and permeability limitations. Buccal administration enables transmucosal absorption bypassing first-pass hepatic metabolism, thereby mitigating gastrointestinal side effects and food effects compared to conventional oral capsule formulations. The disclosure demonstrates a synergistic effect wherein co-formulation of trospium chloride with xanomeline tartrate unexpectedly enhances transmucosal permeation of trospium chloride compared to films containing trospium chloride alone. Methods of treatment and manufacturing processes are also provided.
Resumen de: US20260209771A1
The present disclosure relates to an antisense oligonucleotide suitable for editing an adenosine in a target RNA nucleic acid sequence to inosine (A-to-I editing), wherein the antisense oligonucleotide comprises a sequence that is substantially complementary to the target RNA nucleic acid sequence: 5′-A C U A C A G C A U U G C-3′ (SEQ ID NO: 1), or complementary to a sequence that has at least 80% sequence identity to SEQ ID NO: 1, wherein A is the target adenosine to be edited in the target nucleic acid; and the antisense oligonucleotide can be represented by: 3′-X−5 X−4 X−3 X−2 X−1 X0 X+1 X+2 X+3 X+4 X+5 X+6 X+7-5′, wherein X represents a nucleic acid, X0 represents cytosine (C), deoxycytosine (dC), or uracil (U) directly opposite to the target adenosine to be edited, and wherein there is a mismatch between the antisense oligonucleotide and the target nucleic acid at one or more of the following position(s): a) −5 (X−5); b)+3 (X+3); c)+7 (X+7); d)+7 (X+7) and +2 (X+2); e)+7 (X+7) and −5 (X−5); or f)+6 (X+6) and −5 (X−5).
Nº publicación: US20260207625A1 23/07/2026
Solicitante:
UMECRINE COGNITION AB [SE]
Umecrine Cognition AB
Resumen de: US20260207625A1
0000 The present invention is directed to the compound golexanolone for use in the treatment of Parkinson's Disease (PD) or for use in the treatment of L-dopa Induced Dyskinesia (LID) in Parkinson's Disease (PD) patients. Further, the present invention is directed to the compound golexanolone or a pharmaceutically acceptable salt thereof, for use in the treatment of Parkinson's Diseases (PD) patients, in particular PD patients exhibiting a L-dopa Induced Dyskinesia (LID).
BOPI
Sede Electrónica
